供应WHO13/206可溯源纤维蛋白酶国际标准物质
产品详情如下，更多产品价格和货期，请咨询客服，供实验室使用！
The 4th International Standard for Plasmin (13/206) was established by the Expert Committee on Biological Standardisation of the World Health Organisation in October 2014, and a report of the collaborative study is available from WHO, reference number WHO/BS/2014.2249. WHO13/206
The intended use of this preparation is to standardise potency measurements for plasmin in enzymatic assays. A potency of 8.0 IU/ampoule was assigned in a collaborative study, based on chromogenic assays relative to the 3rd International Standard for Plasmin (97/536).
Active site titration on 13/206 provided an estimate for active enzyme in the ampoule, after reconstitution with 1 ml water, of 1.5 µM; however this is only an estimate from one laboratory and should be treated as a guide. 可溯源纤维蛋白酶国际标准物质
This preparation is not for administration to humans or animals in the human food chain.The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.
第四批次国际质粒标准（13/206）由世界卫生组织生物标准化专家委员会于2014年10月制定，可从世界卫生组织获得合作研究报告，参考号为世界卫生组织/BS/2014.2249。
该制剂的预期用途是在酶测定中对纤溶酶的效力测量进行标准化。在一项合作研究中，根据与第三国际血浆标准（97/536）相关的显色分析，确定了8.0 IU/安瓿的效力。
第13/206天的活性位点滴定提供了安瓿中活性酶的估计值，在用1毫升水重构后，为1.5µM；然而，这只是一个实验室的估计，应该作为指导。
该制剂不适用于人类或人类食物链中的动物。该制剂含有人类来源的物质，其最终产物或来源物质已经检测，HBsAg、抗-HIV和HCV RNA呈阴性。与所有生物来源的材料一样，这种制剂应被视为对健康有潜在危害。应根据您自己实验室的安全程序使用和丢弃它。此类安全程序应包括佩戴防护手套和避免产生气溶胶。打开安瓿或小瓶时应小心，以避免割伤。